Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 6 pages · Chinese
Harbin Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Harbin Pharmaceutical
- Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Heilongjiang Jurisdiction in 2026 and the 2025 Annual and Q1 2026 Performance Briefing
- Announcement on Change of Accounting Policies
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Resolutions of the 24th Meeting of the 10th Board of Directors
- Announcement on Subsidiary's Drug Passing the Consistency Evaluation for Generic Drugs
Later from Harbin Pharmaceutical
- Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Pledge of Partial Shares of Controlling Shareholder
- Announcement on Expected Increase in Semi-annual Performance for 2026
- Announcement on Adjustment to the Company's Products in the National Essential Medicines List
Follow Harbin Pharmaceutical into a list and get an email when it puts out news.
Follow Harbin Pharmaceutical